Citations

Mayo Clinic

Showing 10 of 108599 citations.

Postprandial Plasma Concentrations of ProANP in Patients with Type 2 Diabetes and Healthy Controls
Sonne, David P. , Terzic, Dijana, Knop, Filip K. , Goetze, Jens P. , Goetze, Jens Peter

Clinical Chemistry | March 21, 2017 | Volume: 63 | Issue: 5 | Pages: 1040-1041

10.1373/clinchem.2016.268060 | PMID 28320761 Get It

Iatrogenic thyrotoxicosis and the role of therapeutic plasma exchange
Shah, Kabeer , Mbughuni, Michael M., Burgstaler, Edwin A. , Block, Darci R , Winters, Jeffrey L. , Shah, Kabeer K , Winters, Jeffrey L

Journal of Clinical Apheresis | March 20, 2017 | Volume: 32 | Issue: 6 | Pages: 579-583

10.1002/jca.21536 | PMID 28319287 Get It

AbstractThyroid storm or severe thyrotoxicosis results from extreme thyroid hormone elevation. Therapy includes medical management to prevent hormone production, release, recycling, and peripheral conversion while stabilizing adrenergic tone. Thyroid dysfunction is the usual cause but it can be due to excessive thyroid hormone ingestion. Therapeutic plasma exchange (TPE) has been used to rapidly remove protein‐bound thyroid hormone. American Society for Apheresis guidelines make a weak recommendation to perform TPE in selected patients in the treatment of thyrotoxicosis based on low quality evidence. We present a case of excessive thyroid replacement hormone ingestion treated by TPE. The patient presented with the clinical picture of thyroid storm, including cardiovascular compromise and massively elevated total and free T3 (525 ng/dL, nl 80–200 ng/dL and 28 pg/mL, nl 2.0–3.5 11 pg/mL), which failed medical therapy. A single, one plasma volume TPE was performed. Both total and free T3 demonstrated substantial declines immediately after TPE with the patient's mental status returning to near‐normal. Thyroid hormone extraction efficiency and collection efficacy were calculated as 37.1% and 40.8%, respectively. Prior to discharge on day 6, the patient's compounding pharmacy indicated that a “bad batch” of bovine thyroid gland derived replacement hormone had been produced. TPE appears to be effective in removing protein bound thyroid hormone in extreme iatrogenic thyrotoxicosis.
Evaluation of different recall periods for the US National Cancer Institute’s PRO-CTCAE
Mendoza, Tito R. , Dueck, Amylou C. , Atkinson, Thomas M. , Li, Yuelin , Castro, Kathleen M. , Denicoff, Andrea , Rogak, Lauren J. , Cleeland, Charles S. , Sloan, Jeff A. , Basch, Ethan , Dueck, A. C. , Bennett, Antonia V , Mitchell, Sandra A , Reeve, Bryce B. , Piekarz, Richard , Schrag, Deborah , Basch, Ethan , Mendoza, Tito , Li, Yuelin

Clinical Trials | March 20, 2017 | Volume: 14 | Issue: 3 | Pages: 255-263

10.1177/1740774517698645 | PMID 28545337 Get It

Aims: The US National Cancer Institute recently developed the PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events). PRO-CTCAE is a library of questions for clinical trial participants to self-report symptomatic adverse events (e.g. nausea). The objective of this study is to inform evidence-based selection of a recall period when PRO-CTCAE is included in a trial. We evaluated differences between 1-, 2-, 3-, and 4-week recall periods, using daily reporting as the reference. Methods: English-speaking patients with cancer receiving chemotherapy and/or radiotherapy were enrolled at four US cancer centers and affiliated community clinics. Participants completed 27 PRO-CTCAE items electronically daily for 28 days, and then weekly over 4 weeks, using 1-, 2-, 3-, and 4-week recall periods. For each recall period, mean differences, effect sizes, and intraclass correlation coefficients were calculated to evaluate agreement between the maximum of daily ratings and the corresponding ratings obtained using longer recall periods (e.g. maximum of daily scores over 7 days vs 1-week recall). Analyses were repeated using the average of daily scores within each recall period rather than the maximum of daily scores. Results: A total of 127 subjects completed questionnaires (57% male; median age: 57). The median of the 27 mean differences in scores on the PRO-CTCAE 5-point response scale comparing the maximum daily versus the longer recall period (and corresponding effect size) was −0.20 (−0.20) for 1-week recall, −0.36 (−0.31) for 2-week recall, −0.45 (−0.39) for 3-week recall, and −0.47 (−0.40) for 4-week recall. The median intraclass correlation across 27 items between the maximum of daily ratings and the corresponding longer recall ratings for 1-week recall was 0.70 (range: 0.54–0.82), for 2-week recall was 0.74 (range: 0.58–0.83), for 3-week recall was 0.72 (range: 0.61–0.84), and for 4-week recall was 0.72 (range: 0.64–0.86). Similar results were observed for all analyses using the average of daily scores rather than the maximum of daily scores. Conclusion: A 1-week recall corresponds best to daily reporting. Although intraclass correlations remain stable over time, there are small but progressively larger differences between daily and longer recall periods at 2, 3, and 4 weeks, respectively. The preferred recall period for the PRO-CTCAE is the past 7 days, although investigators may opt for recall periods of 2, 3, or 4 weeks with an understanding that there may be some information loss.
Dermatomyofibromas Arising in Children: Report of Two New Cases and Review of the Literature
Janice, E., Wieland, Carilyn N. , Tollefson, Megha M. , Ma, Janice E

Pediatric Dermatology | March 20, 2017 | Volume: 34 | Issue: 3 | Pages: 347-351

10.1111/pde.13104 | PMID 28318057 Get It

AbstractDermatomyofibroma is a rare, benign mesenchymal proliferation not commonly reported in children. Two patients with biopsy‐proven dermatomyofibroma were identified (one female, one male) at our institution, both with rather atypical clinical presentations. The clinical and histopathologic findings and a review of the literature are presented here. Features of dermatomyofibroma should be recognized and differentiated from those of similar‐appearing entities since the prognosis of this benign tumor is favorable after complete excision.
Expanded traditional melanoma FISH testing versus CAP‐QPCR to identify high‐risk melanocytic lesions
Sominidi‐Damodaran, Sindhuja , Guo, Ruifeng , Meves, Alexander , Bridges, Alina G. , Guo, Ruifeng

International Journal of Dermatology | March 20, 2017 | Volume: 56 | Issue: 9 | Pages: No page available

10.1111/ijd.13596 | PMID 28317107 Get It

Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis
Marshall, Ariela L. , Bartley, Adam C. , Ashrani, Aneel A. , Pruthi, Rajiv K. , Durani, Urshila , Kapoor, Prashant , Hashmi, Shahrukh K. , Siddiqui, Mustaqeem , Siddiqui, Mustaqeem A, Gonsalves, Wilson I. , Go, Ronald S. , Marshall, Ariela , Siddiqui, Mustaqeem A , Durani, Urshila

Vascular Medicine | March 20, 2017 | Volume: 22 | Issue: 2 | Pages: 121-127

10.1177/1358863x17693103 | PMID 28429667 Get It

Venous thromboembolism (VTE) contributes to significant morbidity, mortality, and socioeconomic burden. There is a paucity of literature regarding sex-based sociodemographic differences in VTE presentation and short-term outcomes. We aimed to compare clinical outcomes between men and women hospitalized for VTE management. We performed a retrospective analysis using data from the National Inpatient Sample (NIS) database from 2012 to 2013. Inclusion criteria were age 18 years and older and a primary discharge diagnosis of VTE. Sociodemographic features and medical comorbidities were analyzed, as were hospital length of stay and in-hospital mortality rates. A total of 107,896 patients met the inclusion criteria; 53% were female. Median age was 65 years (interquartile range 51–77) and women were older than men (65 vs 62 years, p<0.001). There were significant differences between men and women with respect to race, primary insurance payer and medical comorbidities, and small differences with respect to VTE location. Female sex was associated with a small but significantly longer hospital length of stay (mean ratio 1.04, 95% CI 1.03–1.05, p<0.001) but no significant difference in in-hospital mortality (2.2% vs 2.1%, p=0.15). In a multivariate model, there was no significant difference between women and men with respect to hospital length of stay or in-hospital mortality. In conclusion, we used data from the NIS to study over 100,000 patients hospitalized for VTE, and identified several sex-based disparities in sociodemographic factors and location of VTE. However, in a multivariable analysis correcting for these factors, sex was not associated with significant differences in clinical outcomes.
Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients
Cousin, Margot A. , Matey, Eric T. , Blackburn, Patrick R. , Boczek, Nicole J. , McAllister, Tammy M., Kruisselbrink, Teresa , Babovic‐Vuksanovic, Dusica , Klee, Eric W. , Kruisselbrink, Teresa M, Lazaridis, Konstantinos N. , Cousin, Margot A

Molecular Genetics & Genomic Medicine | March 20, 2017 | Volume: 5 | Issue: 3 | Pages: 269-279

10.1002/mgg3.283 | PMID 28546997 Get It

AbstractBackgroundWe characterized the pharmacogenomics (PGx) results received by diagnostic odyssey patients as secondary findings during clinical whole exome sequencing (WES) testing as a part of their care in Mayo Clinic's Individualized Medicine Clinic to determine the potential benefits and limitations to this cohort.MethodsWES results on 94 patients included a subset of PGx variants in CYP2C19, CYP2C9, and VKORC1 if identified in the patient. Demographic, phenotypic, and medication usage information was abstracted from patient medical data. A pharmacist interpreted the PGx results in the context of the patients’ current medication use and made therapeutic recommendations.ResultsThe majority was young with a median age of 10 years old, had neurological involvement in the disease presentation (71%), and was currently taking medications (90%). Of the 94 PGx‐evaluated patients, 91% had at least one variant allele reported and 20% had potential immediate implications on current medication use.ConclusionDue to the disease complexity and medication needs of diagnostic odyssey patients, there may be immediate benefit obtained from early life PGx testing for many and most will likely find benefit in the future. These results require conscientious interpretation and management to be actionable for all prescribing physicians throughout the lifetime of the patient.
Kita, Hirohito

Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology | March 18, 2017 | Volume: 14 | Issue: 3 | Pages: 303-303

10.3388/jspaci.14.303 Get It

Acute Changes in Left Atrial Pressure After MitraClip Are Associated With Improvement in 6-Minute Walk Distance
Maor, Elad , Panaich, Sidakpal , Reeder, Guy S., Nishimura, Rick A., Rihal, Charanjit S. , Eleid, Mackram F. , Raphael, Claire E. , Panaich, Sidakpal S, Nkomo, Vuyisile T. , Rihal, Charanjit S. , Panaich, Sidakpal S , Maor, Elad

Circulation: Cardiovascular Interventions | March 18, 2017 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/circinterventions.116.004856 | PMID 28314742 Get It

Background— Data on the clinical use of left atrial (LA) hemodynamic monitoring during MitraClip procedure are limited. This study evaluated the association between intraprocedural changes in LA pressure after MitraClip and improvement in exercise capacity as documented by 6-minute walk test (6MWT). Methods and Results— Study population included 50 patients who underwent MitraClip at the Mayo Clinic (Rochester, MN), between June 2014 and July 2016 and completed both baseline and 30-day follow-up 6MWT. Primary outcome for the current analysis was defined as 6MWT improvement above the median. Mean age of the study population was 79±10 years, and 34 (68%) were men. Baseline preprocedural 6MWT distance was 308 m (interquartile range [IQR], 234–394 m). Acute, intraprocedural change in LA pressure after MitraClip was 3 mm Hg (IQR, 1–6 mm Hg), and change in V wave was 11 mm Hg (IQR, 6–19 mm Hg). Median 6MWT improvement was 25 m (IQR, 19–47 m). Univariate analysis showed that patients with ≤ mild postprocedural mitral regurgitation were 4-fold more likely to experience an improvement in 6MWT ( P =0.02). Multivariate model demonstrated that each 5 mm Hg decrease in V wave was associated with 49% increased likelihood for improvement in 6-minute walk ( P =0.04). Similar model with V-wave change as a dichotomous variable showed that patients with a V-wave decrease of ≥11 mm Hg were 3.8× more likely to improve their 6MWT ( P =0.05). Conclusions— Acute changes in LA pressure after MitraClip procedure are associated with clinical improvement as measured by 6MWT. Continuous LA pressure monitoring may be a useful tool for procedural guidance during transcatheter mitral repair.
Contemporary carotid imaging: from degree of stenosis to plaque vulnerability
Brinjikji, Waleed , Kim, Gyeong‐Moon , Huston, John , Rabinstein, Alejandro A. , Lerman, Amir , Lanzino, Giuseppe

Journal of Neurosurgery | March 17, 2017 | Volume: 2016 | Issue: 1 | Pages: 27-42

10.3171/2015.1.jns142452.test Get It